'''Navitoclax''' (previously '''ABT-263''') is an experimental [[oral administration|orally]] active anti-[[cancer]] [[drug]], which is similar in action to [[obatoclax]], except that unlike obatoclax, it does not have off-target effects.<ref>{{cite journal | last1 = Gandhi | first1 = L. | last2 = Camidge | first2 = D. R. | last3 = de Oliveira | first3 = M. R. | last4 = Bonomi | first4 = P. | last5 = Gandara | first5 = D. | last6 = Khaira | first6 = D. | last7 = Dive | first7 = C. | year = 2011 | title = Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors | journal = Journal of clinical oncology | volume = 29 | issue = 7| pages = 909â€“916 | doi = 10.1200/JCO.2010.31.6208 | pmid=21282543 | pmc=4668282}}</ref><ref>Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., ... & Lowes, K. N. (2015). Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science translational medicine, 7(279), 279ra40-279ra40. {{DOI|10.1126/scitranslmed.aaa4642}}</ref>

 
== Effects against senescent cells ==
